BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1428 related articles for article (PubMed ID: 19617339)

  • 21. Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer.
    Gourin CG; Watts TL; Williams HT; Patel VS; Bilodeau PA; Coleman TA
    Laryngoscope; 2008 Apr; 118(4):671-5. PubMed ID: 18197136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N2 disease in patients with head and neck squamous cell cancer treated with chemoradiotherapy: is there a role for posttreatment neck dissection?
    Cho AH; Shah S; Ampil F; Bhartur S; Nathan CO
    Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1112-8. PubMed ID: 19917924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers.
    Breen SL; Publicover J; De Silva S; Pond G; Brock K; O'Sullivan B; Cummings B; Dawson L; Keller A; Kim J; Ringash J; Yu E; Hendler A; Waldron J
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):763-70. PubMed ID: 17379435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diffusion-weighted MRI for nodal staging of head and neck squamous cell carcinoma: impact on radiotherapy planning.
    Dirix P; Vandecaveye V; De Keyzer F; Op de Beeck K; Poorten VV; Delaere P; Verbeken E; Hermans R; Nuyts S
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):761-6. PubMed ID: 19540069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes].
    Zhao TT; Li JG; Li YM
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):206-9. PubMed ID: 17649638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limitations of PET/CT in determining need for neck dissection after primary chemoradiation for advanced head and neck squamous cell carcinoma.
    Lyford-Pike S; Ha PK; Jacene HA; Saunders JR; Tufano RP
    ORL J Otorhinolaryngol Relat Spec; 2009; 71(5):251-6. PubMed ID: 19776658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
    Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
    J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography (PET) in the staging of head neck cancer: comparison between PET and CT.
    Bruschini P; Giorgetti A; Bruschini L; Nacci A; Volterrani D; Cosottini M; Ursino F; Mariani G; Fattori B
    Acta Otorhinolaryngol Ital; 2003 Dec; 23(6):446-53. PubMed ID: 15198047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography.
    Pfau PR; Perlman SB; Stanko P; Frick TJ; Gopal DV; Said A; Zhang Z; Weigel T
    Gastrointest Endosc; 2007 Mar; 65(3):377-84. PubMed ID: 17321235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET monitoring of therapy response in head and neck squamous cell carcinoma.
    Schöder H; Fury M; Lee N; Kraus D
    J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma.
    Quon A; Fischbein NJ; McDougall IR; Le QT; Loo BW; Pinto H; Kaplan MJ
    J Nucl Med; 2007 Jan; 48 Suppl 1():58S-67S. PubMed ID: 17204721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
    Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients.
    Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Kotani Y; Nishimura Y; Higashino T; Sugimura K
    J Magn Reson Imaging; 2007 Sep; 26(3):498-509. PubMed ID: 17729341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole-body MRI for metastases screening: a preliminary study using 3D VIBE sequences with automatic subtraction between noncontrast and contrast enhanced images.
    Thomson V; Pialat JB; Gay F; Coulon A; Voloch A; Granier A; Guérin JC; Viallon M; Berthezene Y
    Am J Clin Oncol; 2008 Jun; 31(3):285-92. PubMed ID: 18525309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of distant metastases in patients with oesophageal or gastric cardia cancer: a diagnostic decision analysis.
    van Vliet EP; Steyerberg EW; Eijkemans MJ; Kuipers EJ; Siersema PD
    Br J Cancer; 2007 Oct; 97(7):868-76. PubMed ID: 17848957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The additional value of integrated PET/CT over PET in initial lymph node staging of esophageal cancer.
    Kato H; Kimura H; Nakajima M; Sakai M; Sano A; Tanaka N; Inose T; Faried A; Saito K; Ieta K; Sohda M; Fukai Y; Miyazaki T; Masuda N; Fukuchi M; Ojima H; Tsukada K; Oriuchi N; Endo K; Kuwano H
    Oncol Rep; 2008 Oct; 20(4):857-62. PubMed ID: 18813827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data.
    Martinez-Möller A; Souvatzoglou M; Delso G; Bundschuh RA; Chefd'hotel C; Ziegler SI; Navab N; Schwaiger M; Nekolla SG
    J Nucl Med; 2009 Apr; 50(4):520-6. PubMed ID: 19289430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
    Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
    Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variability of gross tumor volume delineation in head-and-neck cancer using PET/CT fusion, Part II: the impact of a contouring protocol.
    Berson AM; Stein NF; Riegel AC; Destian S; Ng T; Tena LB; Mitnick RJ; Heiba S
    Med Dosim; 2009; 34(1):30-5. PubMed ID: 19181253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 72.